KR20190134809A - 베타 세크레타제 억제를 위한 조성물 및 방법 - Google Patents

베타 세크레타제 억제를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20190134809A
KR20190134809A KR1020197034396A KR20197034396A KR20190134809A KR 20190134809 A KR20190134809 A KR 20190134809A KR 1020197034396 A KR1020197034396 A KR 1020197034396A KR 20197034396 A KR20197034396 A KR 20197034396A KR 20190134809 A KR20190134809 A KR 20190134809A
Authority
KR
South Korea
Prior art keywords
secretase
oroxylin
chrysine
disease
bicalane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197034396A
Other languages
English (en)
Korean (ko)
Inventor
칼야남 나가브후스하남
무하메드 마지드
Original Assignee
새미 랩스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 새미 랩스 리미티드 filed Critical 새미 랩스 리미티드
Publication of KR20190134809A publication Critical patent/KR20190134809A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Confectionery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197034396A 2017-06-15 2018-06-14 베타 세크레타제 억제를 위한 조성물 및 방법 Ceased KR20190134809A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762520141P 2017-06-15 2017-06-15
US62/520,141 2017-06-15
PCT/US2018/037454 WO2018232063A1 (en) 2017-06-15 2018-06-14 Compositions and methods for beta secretase inhibition

Publications (1)

Publication Number Publication Date
KR20190134809A true KR20190134809A (ko) 2019-12-04

Family

ID=64655980

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197034396A Ceased KR20190134809A (ko) 2017-06-15 2018-06-14 베타 세크레타제 억제를 위한 조성물 및 방법
KR1020197033007A Ceased KR20190131589A (ko) 2017-06-15 2018-06-15 신경보호 조성물 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197033007A Ceased KR20190131589A (ko) 2017-06-15 2018-06-15 신경보호 조성물 및 이의 용도

Country Status (9)

Country Link
US (2) US11458117B2 (https=)
EP (2) EP3638277B1 (https=)
JP (2) JP7209645B2 (https=)
KR (2) KR20190134809A (https=)
CA (2) CA3063751C (https=)
ES (1) ES3005508T3 (https=)
FI (1) FI3638277T3 (https=)
PL (2) PL3638277T3 (https=)
WO (2) WO2018232063A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3005508T3 (en) * 2017-06-15 2025-03-14 Sami Labs Ltd Compositions and methods for beta secretase inhibition
US12465585B2 (en) * 2018-06-15 2025-11-11 Sami-Sabinsa Group Limited Compositions for the management of seizure induced neurotoxicity
CN110115712A (zh) * 2019-07-04 2019-08-13 兰州大学 一种同时激活氧化磷酸化通路和抑制糖酵解途径的激活剂及其应用
CN114630650B (zh) * 2019-08-26 2024-03-29 萨米-萨宾莎集团有限公司 植物活性物及其防污染效果
CN114246879B (zh) * 2021-12-30 2023-10-27 沈阳兴齐眼药股份有限公司 木蝴蝶苷b在制备用于预防、控制和/或治疗眼部疾病药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101837003B (zh) * 2002-04-30 2013-09-04 尤尼根公司 作为治疗剂的包含无取代b环类黄酮和黄烷混合物的组合物
US8945518B2 (en) * 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
US8034387B2 (en) * 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
MXPA06002456A (es) * 2003-09-02 2006-08-31 Unigen Pharmaceuticals Inc Formulacion de una mezcla de flavonoides con el aniillo b libre y flavanos para utilizarse en la prevencion y tratamiento de la declinacion cognoscitiva y el deterioro de la memoria relacionado con la edad.
US7855200B2 (en) * 2006-01-09 2010-12-21 Council Of Scientific And Industrial Research Method for treatment of gastric ulcers and ulcers induced by aspirin
JP2009527541A (ja) 2006-02-21 2009-07-30 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 腸管αグルコシダーゼ阻害剤ならびにその単離方法およびその使用
US20100029654A1 (en) 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
KR20080008929A (ko) * 2006-11-20 2008-01-24 대한민국(관리부서 식품의약품 안전청장) 오록실린 ａ를 함유하는 인지 기능 장애 관련 질환의 예방및 개선용 건강기능식품
US20150231067A1 (en) * 2012-08-29 2015-08-20 Mannkind Corporation Method and composition for treating hyperglycemia
NZ753943A (en) * 2016-11-11 2021-03-26 Sami Labs Ltd Composition containing oroxylin a and method of extraction thereof
ES3005508T3 (en) 2017-06-15 2025-03-14 Sami Labs Ltd Compositions and methods for beta secretase inhibition

Also Published As

Publication number Publication date
WO2018232063A1 (en) 2018-12-20
EP3638278B1 (en) 2022-05-11
EP3638278A4 (en) 2021-03-17
US20180360800A1 (en) 2018-12-20
FI3638277T3 (fi) 2025-01-10
US11458117B2 (en) 2022-10-04
EP3638277A1 (en) 2020-04-22
ES3005508T3 (en) 2025-03-14
EP3638277A4 (en) 2021-03-17
WO2018232224A1 (en) 2018-12-20
CA3063751A1 (en) 2018-12-20
CA3063757C (en) 2023-08-01
PL3638278T3 (pl) 2022-10-03
EP3638277B1 (en) 2024-10-09
US20180360801A1 (en) 2018-12-20
JP7209645B2 (ja) 2023-01-20
US10894029B2 (en) 2021-01-19
EP3638278A1 (en) 2020-04-22
JP2020523342A (ja) 2020-08-06
KR20190131589A (ko) 2019-11-26
JP6796217B2 (ja) 2020-12-02
PL3638277T3 (pl) 2025-03-10
JP2020523372A (ja) 2020-08-06
CA3063757A1 (en) 2018-12-20
CA3063751C (en) 2023-01-03

Similar Documents

Publication Publication Date Title
Martín-Maestro et al. Slower dynamics and aged mitochondria in sporadic Alzheimer’s disease
KR20190134809A (ko) 베타 세크레타제 억제를 위한 조성물 및 방법
Corpas et al. SIRT1 overexpression in mouse hippocampus induces cognitive enhancement through proteostatic and neurotrophic mechanisms
Delport et al. The amyloid precursor protein: A converging point in Alzheimer’s disease
Dong et al. Advances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesis
Gerson et al. Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species
Upadhya et al. Role of the ubiquitin proteasome system in Alzheimer's disease
Lahiri et al. Current drug targets for Alzheimer's disease treatment
Sivak The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease
Mori et al. Ferulic acid is a nutraceutical β-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice
Xu et al. Amyloid-β peptides are cytotoxic to oligodendrocytes
Grimm et al. The impact of cholesterol, DHA, and sphingolipids on Alzheimer’s disease
Zhang Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer’s disease
Hoppe et al. SUMOylation: novel neuroprotective approach for Alzheimer’s disease?
Prasad et al. Prostaglandins as putative neurotoxins in Alzheimer's disease
Perone et al. Mitochondrial SIRT3 deficiency results in neuronal network hyperexcitability, accelerates age-related Aβ pathology, and renders neurons vulnerable to Aβ toxicity
Acewicz et al. Incidence and morphology of secondary TDP-43 proteinopathies: Part 1
Jacobsen Alzheimer's disease: an overview of current and emerging therapeutic strategies
Chiu et al. Progressive Neurodegeneration of Retina in Alzheimer’s Disease—Are β-Amyloid Peptide and Tau New Pathological Factors in Glaucoma?
Ohm et al. Cholesterol, statins and tau
WO2008036733A2 (en) Methods for treatment of vesicle transport disorders
CN117202911A (zh) 包含作为活性成分的刺五加苷b的用于治疗神经炎症的药物组合物
Creed et al. Amyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implications
Erdemci et al. Etiology and histopathology of alzheimer’s disease and current approaches
US20210113552A1 (en) Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6

Legal Events

Date Code Title Description
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000